#1 Clinical Trials Search in Europe

Teplizumab

Teplizumab is an innovative drug being studied in clinical trials for its potential to delay or prevent the onset of type 1 diabetes (T1D). This article explores the use of teplizumab in various clinical trials, focusing on its efficacy, safety, and potential benefits for individuals at risk of developing T1D or those recently diagnosed with the condition.

Table of Contents

What is Teplizumab?

Teplizumab is a medication that has shown promise in the treatment and prevention of type 1 diabetes (T1D). It is also known by other names such as TZIELD®, hOKT3gamma1(Ala-Ala), and MGA031[1]. This drug belongs to a class of medications called monoclonal antibodies, which are laboratory-made proteins designed to target specific cells in the body.

How Does Teplizumab Work?

Teplizumab works by targeting and modifying the behavior of certain immune cells in the body. In type 1 diabetes, the immune system mistakenly attacks and destroys the insulin-producing cells in the pancreas. Teplizumab is designed to interrupt this process by:

  • Binding to a specific protein (CD3) on the surface of T cells, a type of immune cell
  • Modifying the function of these T cells to prevent them from attacking insulin-producing cells
  • Potentially preserving the remaining insulin-producing cells in the pancreas
By doing this, teplizumab aims to slow down or prevent the progression of type 1 diabetes[2].

What Conditions Does Teplizumab Treat?

Teplizumab is primarily being studied and used for:

  • Prevention of type 1 diabetes: In individuals who are at high risk of developing T1D but have not yet been diagnosed[2]
  • Treatment of recent-onset type 1 diabetes: In people who have been recently diagnosed with T1D[1]
  • Stage 2 type 1 diabetes: This is an early stage of T1D where blood sugar levels are becoming abnormal but not yet high enough to be diagnosed as full-blown diabetes[3]
It’s important to note that teplizumab is not a cure for type 1 diabetes, but it may help delay its onset or slow its progression.

How is Teplizumab Administered?

Teplizumab is typically administered in the following ways:

  • Intravenous (IV) infusion: The most common method, where the drug is given directly into a vein over a period of time
  • Subcutaneous injection: Some studies are exploring the possibility of administering teplizumab as an injection under the skin
The treatment course usually involves daily doses for 12-14 consecutive days. The exact dosage may vary depending on the specific study or treatment plan[2].

Teplizumab in Clinical Trials

Several clinical trials have been conducted or are ongoing to evaluate the effectiveness and safety of teplizumab:

  • Prevention trial: A study showed that teplizumab could delay the onset of type 1 diabetes in high-risk individuals by an average of 2 years[2]
  • Recent-onset T1D trial: Research has indicated that teplizumab may help preserve insulin production in people recently diagnosed with T1D[1]
  • Combination therapy: Some studies are exploring the use of teplizumab in combination with other treatments, such as AG019, to potentially enhance its effectiveness[4]
These trials are crucial in determining the long-term benefits and potential uses of teplizumab in managing type 1 diabetes.

Safety and Side Effects

As with any medication, teplizumab can cause side effects. Some of the potential side effects and safety concerns include:

  • Cytokine release syndrome: A condition that can cause fever, rash, and other flu-like symptoms
  • Infections: There may be an increased risk of infections due to the effect on the immune system
  • Hypersensitivity reactions: Allergic-type reactions to the medication
  • Lymphoproliferative disorders: Rare conditions involving the overgrowth of lymphoid cells
Researchers are closely monitoring these and other potential side effects in ongoing clinical trials[3]. It’s important for patients to discuss the potential risks and benefits with their healthcare provider.

Future Research and Potential

The development of teplizumab represents an exciting advancement in the field of type 1 diabetes treatment and prevention. Ongoing and future research aims to:

  • Further understand the long-term effects of teplizumab
  • Explore its use in different stages of type 1 diabetes
  • Investigate combination therapies with other treatments
  • Assess its safety and effectiveness in larger populations
As research progresses, teplizumab may become an important tool in the management of type 1 diabetes, potentially offering hope for delaying or preventing the onset of this chronic condition[3].

Aspect Details
Drug Name Teplizumab (also known as PRV-031, TZIELD, MGA031)
Type of Drug Anti-CD3 monoclonal antibody
Primary Use Delay or prevent onset of type 1 diabetes in at-risk individuals; slow disease progression in recent-onset T1D
Administration Intravenous infusion, typically 12-14 day course
Target Population Individuals at high risk for T1D; recently diagnosed T1D patients (4-12 months post-diagnosis)
Age Range in Trials 8-45 years old (varies by study)
Primary Outcomes C-peptide levels, rate of progression to T1D, insulin use, HbA1c levels
Safety Monitoring Adverse events, cytokine release syndrome, infections, hypersensitivity reactions, blood cell count changes
Ongoing Research Long-term safety, efficacy in different age groups, combination therapies, subcutaneous administration

FAQ

  • What is teplizumab and how does it work? Teplizumab is an anti-CD3 monoclonal antibody that targets the immune system. It works by modifying T cells, which are involved in the autoimmune attack on insulin-producing beta cells in the pancreas. By doing so, teplizumab aims to delay or prevent the onset of type 1 diabetes in at-risk individuals or slow the progression of the disease in those recently diagnosed.
  • Who is eligible for teplizumab treatment in clinical trials? Eligibility varies depending on the specific trial, but generally includes individuals at high risk for developing type 1 diabetes (such as those with autoantibodies) and people recently diagnosed with type 1 diabetes. Some trials focus on specific age groups, ranging from children as young as 8 years old to adults up to 45 years of age.
  • How is teplizumab administered in clinical trials? In most trials, teplizumab is administered through intravenous (IV) infusion. The typical treatment course involves daily infusions for 12-14 consecutive days. Some studies are also exploring subcutaneous administration of the drug.
  • What are the potential benefits of teplizumab treatment? Clinical trials suggest that teplizumab may delay the onset of type 1 diabetes in high-risk individuals and potentially slow the loss of insulin production in those recently diagnosed. This could lead to better blood sugar control and reduced insulin requirements for patients.
  • What are the main safety concerns being monitored in teplizumab trials? Researchers are closely monitoring for adverse events, including cytokine release syndrome, serious infections, hypersensitivity reactions, and changes in blood cell counts. Long-term safety is also being assessed, including potential effects on pregnancy and fetal development in relevant populations.

Ongoing Clinical Trials on Teplizumab

  • A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

    Recruiting

    1 1
    Investigated drugs:
    Belgium Czechia France Germany Greece Italy +4

  • A Study of Long-Term Safety of Teplizumab in Children and Adolescents with Recently Diagnosed Type 1 Diabetes

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium Czechia France Germany Poland

Glossary

  • Type 1 Diabetes (T1D): An autoimmune condition where the body's immune system attacks and destroys insulin-producing beta cells in the pancreas, leading to little or no insulin production and the need for lifelong insulin therapy.
  • Teplizumab: An anti-CD3 monoclonal antibody being studied for its potential to delay or prevent the onset of type 1 diabetes in at-risk individuals or slow disease progression in those recently diagnosed.
  • C-peptide: A substance produced along with insulin by the pancreas. Measuring C-peptide levels helps assess the body's natural insulin production and is often used as an outcome measure in diabetes clinical trials.
  • Autoantibodies: Antibodies that mistakenly target and react to a person's own tissues or organs. In type 1 diabetes, the presence of certain autoantibodies indicates an increased risk of developing the disease.
  • Mixed Meal Tolerance Test (MMTT): A test used to measure the body's insulin production in response to a standardized meal, often used in diabetes clinical trials to assess beta cell function.
  • Hemoglobin A1c (HbA1c): A blood test that measures average blood sugar levels over the past 2-3 months, used to diagnose diabetes and monitor long-term blood sugar control.
  • Cytokine Release Syndrome: A potential side effect of some immunotherapies, including teplizumab, characterized by fever, nausea, headache, rash, rapid heartbeat, low blood pressure, and trouble breathing.
  • Stage 2 Type 1 Diabetes: An early stage of T1D characterized by the presence of autoantibodies and abnormal blood sugar levels, but without clinical symptoms or the need for insulin therapy.

References

  1. https://clinicaltrials.gov/study/NCT00378508
  2. https://clinicaltrials.gov/study/NCT01030861
  3. https://clinicaltrials.gov/study/NCT06481904
  4. https://clinicaltrials.gov/study/NCT03751007